s&o logo
  • News
  • Trade Ideas
  • Education
  • Community
Sign Up!
News

Calix Shares Move Lower on Mixed Q1 and Weak Guidance

April 22, 2024 George Levine No comments yet

Calix (CALX) stock dipped after the company reported mixed first quarter financial results and issued weak second quarter guidance. Here’s a look:

  • Q1 revenue: $226.31 million, missing the $228.139 million estimate
  • Q1 adjusted EPS: $0.21, beating the $0.20 estimate

The company issued guidance, which is also putting selling pressure on the stock as it’s below estimates for both second quarter adjusted EPS and revenue.

Adjusted EPS GuidanceEstimateRevenue GuidanceEstimate
Q2$0.03 to $0.09$0.24$197 million to $203 million$232.76 million
Calix Second Quarter Guidance Versus Estimates

Calix highlighted its continued success and growth in the platform, cloud, and managed services sectors. But, also noted ongoing challenges in the appliance (hardware systems) segment of its business.

Against the current crosswinds that are still prevalent across our industry, we generated revenue of
$226.3 million, which was within the guidance range provided in January, and produced our fourth
consecutive quarter of double-digit free cash flow, further strengthening our already strong balance
sheet.

Calix First Quarter Letter to Stockholders

The company has a conference call scheduled for tomorrow at 8:30 AM.

Calix stock traded 15.4% lower to $25.01 on heavy volume following the announcement. The stock has a 52-week high of $29.71 and a 52-week low of $29.01.

  • Earnings

Post navigation

Previous
Next

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Search

Categories

  • Education (15)
  • Featured (46)
  • News (85)
  • Trade Ideas (39)

Recent posts

  • FDA Closes Inspection of BioXcel’s TRANQUILITY II Trial Site, Reinforcing Data Integrity
  • Telomir Pharmaceuticals Breakthrough in Silver-Based Medicine
  • flyExclusive to Acquire Jet.AI’s Aviation Business in Strategic Expansion

Tags

BDRX CDT Conduit Conference Call CURR CURRENC Earnings Evergreen GH Research GHRS Grail GRAL HOLO IINN Inspira Technologies Interview IPWR JTAI KULR LCID Litigation LLY Lucid Motors M&A MedTech MicroCloud Movers MSTR My Size MYSZ News NLSP Novo Nordisk NVO Options Partnerships QNTM Quantum BioPharma Stock Market Stocks TAOP TELO Telomir Pharmaceuticals Traws Pharma TRWS

Continue reading

Featured, News, Trade Ideas

NLS Pharmaceutics and Kadimastem Move Closer to Merger Approval

January 31, 2025 Elisa Clay No comments yet

NLS Pharmaceutics (Nasdaq: NLSP) and Kadimastem (TASE: KDST) have reached a key milestone in their planned merger after Kadimastem’s shareholders approved the deal in a special general meeting. The merger aims to create a Nasdaq-listed biotechnology company with a strong portfolio of treatments for neurodegenerative diseases and diabetes. NLS is now preparing to hold its […]

Featured, News, Trade Ideas

Nukkleus Shares Surge 60% Amid Investor Optimism

January 17, 2025 Elisa Clay No comments yet

Nukkleus Inc. (NASDAQ: NUKK) saw its stock skyrocket by 60% during today’s trading session, marking a significant uptick in investor interest and market activity. The surge comes amid heightened speculation about the company’s growth prospects and potential strategic moves. While no major announcements were made by the company, the sharp increase in share price suggests […]

Featured, News, Trade Ideas

Inspira Technologies Ramps Up Production Readiness Amid hMPV Outbreak

January 10, 2025 Elisa Clay No comments yet

Inspira Technologies (Nasdaq: IINN), a leader in life-support technology innovation, has announced preparations for a potential production increase of its INSPIRA ART100 device. This proactive step comes in response to a recent outbreak of human metapneumovirus (hMPV) in China, which has brought renewed attention to the global need for advanced respiratory care solutions. The company […]

s&o logo

Our primary goal is to empower retail investors with helpful news, guides and trading ideas.

Helpful Links
  • News
  • Trade Ideas
  • Education
  • Community
Resources
  • Privacy Policy
  • Terms & Conditions
  • Contact
Get in touch
  • Email us!

© Copyright 2024, stocks&options. All Rights Reserved.